Lupin Gives Direction On Pegfilgrastim And Ranibizumab
Neulasta Biosimilar Previously Slated For FY2021
Indian major Lupin is continuing to further efforts on its three main growth drivers: biosimilars, inhalation products and long-acting injectables, management told the virtual J.P. Morgan Healthcare Conference in San Francisco.
